MedTrace Logo

The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction

NCT06732648 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 725

Last updated 2025-08-22

No results posted yet for this study

Summary

The study is being conducted to evaluate the efficacy, and safety of HRS8179 injection in preventing and treating severe cerebral edema after large area cerebral infarction in the cerebral hemisphere

Conditions

  • Severe Cerebral Edema Following Large Hemispheric Infarction

Interventions

DRUG

HRS8179 injection

HRS8179 injection; high dose

DRUG

HRS8179 blank preparation.

HRS8179 blank preparation.

Sponsors & Collaborators

  • Beijing Suncadia Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-07
Primary Completion
2027-06-30
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06732648 on ClinicalTrials.gov